(In April 28 story, corrects company name in paragraph 1. The story was previously corrected to fix a typo in the headline.)
April 28 (Reuters) - A panel of U.S. Food and Drug Administration advisers on Friday voted for the expanded use of British drugmaker AstraZeneca Plc's experimental treatment, jointly developed with Merck & Co, for a type of prostate cancer.
The FDA panel voted 11-1 with one abstention, in favor of using the drug, Lynparza, in combination with other medications – abiraterone and prednisone or prednisolone – to treat a type of treatment-resistant prostate cancer in adult patients. (Reporting by Mariam Sunny, Khushi Mandowara and Aditya Samal in Bengaluru; Editing by Shailesh Kuber)
